Pradel Vincent, Tardieu Sophie, Micallef Joëlle, Signoret Anne, Villano Philippe, Gauthier Laurence, Vanelle Patrice, Blin Olivier
Assistance Publique des Hôpitaux de Marseille, France.
Pharmacoepidemiol Drug Saf. 2007 Jan;16(1):79-85. doi: 10.1002/pds.1328.
Use of albumin (indications and quantities involved) has not been assessed in France since major changes occurred after the publication of Cochrane group meta-analysis. The objectives of this study were to measure the repartition of albumin indications in three French university hospitals in 2004 and to assess the feasibility and usefulness to implement a prescription-monitoring program.
Exhaustive record of albumin prescription during 2 months in three French university hospitals of Marseille. Inclusion of all patients with a first prescription of albumin between 15 March 2004 and 15 May 2004. Indication, formulation and quantity prescribed were recorded for each prescription.
One hundred and eighty-seven patients received a total of 426 prescriptions for a total quantity of 21 094 g of albumin during the study. The first indications were hypoalbuminemia (33% of total quantity), plasmapheresis (30.2%) and ascites or hepatorenal syndrome (13.7%). Fifty per cent of total quantity was used by 14 patients (7.5% of included patients).
Most of albumin consumption in our study is concentrated on recognized indications or indications without alternative to albumin. The different levels of analysis (number of patient treated, number of prescription and quantities used) must be taken into account when analyzing medications such as albumin. Only a marginal proportion of consumption is expected to be saved with close monitoring of indications.
自Cochrane小组荟萃分析发表后出现重大变化以来,法国尚未对白蛋白的使用(涉及的适应症和用量)进行评估。本研究的目的是测定2004年法国三家大学医院白蛋白适应症的分布情况,并评估实施处方监测项目的可行性和实用性。
对马赛的三家法国大学医院2个月内的白蛋白处方进行详尽记录。纳入2004年3月15日至2004年5月15日首次开具白蛋白处方的所有患者。记录每张处方的适应症、制剂和处方用量。
在研究期间,187名患者共接受了426张白蛋白处方,总量为21094克。首要适应症为低白蛋白血症(占总量的33%)、血浆置换(30.2%)以及腹水或肝肾综合征(13.7%)。14名患者(占纳入患者的7.5%)使用了总量的50%。
在我们的研究中,大部分白蛋白消耗集中在公认的适应症或没有白蛋白替代物的适应症上。在分析白蛋白等药物时,必须考虑不同层面的分析(接受治疗的患者数量、处方数量和使用量)。通过密切监测适应症,预计只能节省少量的消耗量。